Lucentis ranibizumab regulatory update

The U.K.'s NICE issued final guidance recommending the use of Lucentis ranibizumab from Novartis to treat macular edema secondary to central retinal vein occlusion (CRVO) and secondary to branch retinal vein occlusion (BRVO) for a subset of patients for whom laser photocoagulation has not worked or is not suitable. The recommendation is contingent on Novartis providing Lucentis at an undisclosed discount under a revised patient access scheme and is in line with an April final appraisal determination (see BioCentury, April 15). ...